Centerview's Tokat Sees Potential for Mega Pharma Deals

Bloomberg
Loading video player...
Centerview's Tokat Sees Potential for Mega Pharma Deals
Bloomberg
Written by Bloomberg
Share

Conditions could be ripe for the first $20 billion-plus biopharma deal in more than three years, according to Centerview Partners Co-President Eric Tokat. Tokat and Paul Weiss's Krishna Veeraraghavan joined Dani Burger and Michelle F. Davis on "Bloomberg Deals" for a roundtable to discuss their outlooks for biopharma M&A.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.